This review assessed the effectiveness and safety of isolated limb perfusion for malignant melanoma and concluded that isolated limb perfusion was safe and effective in achieving clinical responses in patients with unresectable locally advanced melanoma of the limbs. Several potential limitations in the review process made the reliability of the authors' conclusions unclear.
Authors' objectives
To assess the effectiveness and safety of isolated limb perfusion for malignant melanoma.
Searching
The authors searched MEDLINE, EMBASE and The Cochrane Library for relevant studies published in English between 1990 and 2008. Search terms were reported. Systematic reviews, retrieved articles and textbooks were searched for further relevant studies.
Study selection
Eligible studies were randomised clinical trials (RCTs), cohort studies, case-control studies or case series that enrolled patients who had unresectable malignant melanoma (stage IIIB and IIIC using American Joint Committee on Cancer definitions) of the limbs. Patients in eligible studies were treated with any regimen of isolated limb perfusion at any temperature level (hyperthermia or normothermia) with any concomitant chemotherapy drug regimen. Eligible studies had to report follow-up and report and analyse efficacy or effectiveness endpoints such as clinical response, survival, recurrence rate and limb salvage rate as well as safety outcomes assessing regional and/or systemic toxicity. Toxicity outcomes were extracted using the Wieberdink classification system for regional toxicity and common terminology criteria for adverse events (version 3) or World Health Organisation classification of chemotherapy toxicity for systemic toxicity.
Within included studies, the average patient age was 61 years. All chemotherapy regimens included melphalan. In most cases with tumoral necrosis factor α was either available as an option or used in all patients. Additional treatments included dacarbazine and cisplatin. Most studies evaluated effectiveness either with or without toxicity; two studies evaluated toxicity only.
Studies were selected by three reviewers independently. Differences between reviewers were resolved by consensus.
Assessment of study quality
A quality assessment was performed using the SIGN checklist of internal validity, study description and overall study assessment.
The authors did not state how many reviewers carried out the quality assessment.
Data extraction
The reviewers extracted the proportion of patients who achieved either a complete response or partial response to isolated limb perfusion and five-year disease free survival, overall survival and overall response. Recurrence rate and limb salvage rate were extracted as secondary outcomes.
The number of reviewers who performed data extraction was not reported.
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Methods of synthesis
A narrative synthesis was presented in which summaries were grouped into clinical response, survival, secondary effectiveness endpoints and toxicity. Primary outcomes included overall survival, disease-free survival, overall response and clinical response. The reviewers reported descriptive statistics; these included range and median average. Subgroup comparisons investigated the effect of temperature regimen, gender, disease stage and repeated treatment.
Results of the review
Twenty-two studies (2,018 isolated limb perfusions, range six to 415) were included in the review: 20 were observational studies and two randomised clinical trials. No detailed study quality results were reported.
Clinical response was reported in 20 studies. Median overall response was 90.4% (range 64% to 100%). Median clinical response was 58.2% (range 25% to 89%). Overall survival or disease-free survival was reported in 14 studies. The median five-year overall survival rate was 37% (range 19% to 50%; eight studies). The median overall survival interval was 36.7 months (range 23.5 months to 69.6 months). Four studies reported five-year disease-free survival rate; the median survival rate was 40% (range 16% to 53%). The median disease-free survival interval was 16 months (range six months to 26 months).
Local recurrence after clinical response to isolated limb perfusion was evaluated in 10 studies. Median recurrence rate was 41% (range 15% to 56%). The interval for development of recurrence after isolated limb perfusion was measured in seven studies. Median time was 10.5 months (range 6 to 30 months). Two studies (n=48) reported limb salvage rates: 95% in one study and 100% in the other. Fifteen studies (n=1,483) reported regional toxicity associated with isolated limb perfusion. Median grade II toxicity was 74%. Median grade III toxicity was 17%. Median grade IV toxicity was 2%. Median grade V toxicity (amputation due to regional toxicity) was 1%.
Six studies (n=562) reported clinical response to isolated limb perfusion with melphalan alone. Median clinical response was 47% (range 25% to 76%). Twelve studies reported clinical response to isolated limb perfusion with melphalan combined with tumour necrosis factor. Median clinical response was 69% (range 26% to 89%). Two studies allowed a direct comparison between isolated limb perfusion with melphalan alone, and isolated limb perfusion with melphalan and tumour necrosis factor. They reported no statistically significant difference between regimens.
Subgroup analysis results were reported.
